title: Racial differences in outcomes of triple-negative breast cancer.
abstract: African American (AA) women have a higher incidence of triple-negative breast cancer (TNBC: negative for the expression of estrogen receptor, progesterone receptor, and HER2 gene amplification) than Caucasian (CA) women, explaining in part their higher breast cancer mortality. However, there have been inconsistent data in the literature regarding survival outcomes of TNBC in AA versus CA women. We performed a retrospective chart review on 493 patients with TNBC first seen at the Washington University Breast Oncology Clinic (WUBOC) between January 2006 and December 2010. Analysis was done on 490 women (30 % AA) for whom follow-up data was available. The median age at diagnosis was 53 (23-98) years and follow-up time was 27.2 months. There was no significant difference between AA and CA women in the age of diagnosis, median time from abnormal imaging to breast biopsy and from biopsy diagnosis to surgery, duration of follow-up, tumor stage, grade, and frequency of receiving neoadjuvant or adjuvant chemotherapy and pathologic complete response rate to neoadjuvant chemotherapy. There was no difference in disease free survival (DFS) and overall survival (OS) between AA and CA groups by either univariate or multivariate analysis that included age, race, and stage. The hazard ratio for AA women was 1.19 (CI 0.80-1.78, p = 0.39) and 0.91 (CI 0.62-1.35, p = 0.64) for OS and DFS, respectively. Among the 158 patients who developed recurrence or presented with stage IV disease (AA: n = 36, CA: n = 122), no racial differences in OS were observed. We conclude that race did not significantly affect the clinical presentation and outcome of TNBC in this single center study where patients received similar therapy and follow-up.
authors: Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors: Jose M
authors: JM
authors: Pacheco
authors: Feng
authors: F
authors: Gao
authors: Caroline
authors: C
authors: Bumb
authors: Matthew J
authors: MJ
authors: Ellis
authors: Cynthia X
authors: CX
authors: Ma
mesh_terms: D000328:Adult; D001741:Black or African American; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D011960:Receptors, Estrogen / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D012189:Retrospective Studies; D016019:Survival Analysis; D014861:Washington / Q000453:epidemiology / Q000208:ethnology; D044465:White People
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
references: JAMA. 2005 Oct 12;294(14):1765-72
references: 16219879
references: Cancer. 2004 Apr 15;100(8):1595-604
references: 15073845
references: J Clin Oncol. 2003 Feb 15;21(4):602-6
references: 12586795
references: J Natl Cancer Inst. 2012 Mar 7;104(5):406-14
references: 22250182
references: JAMA. 1998 Jun 10;279(22):1801-7
references: 9628711
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Ann Intern Med. 2006 Apr 18;144(8):541-53
references: 16618951
references: Breast Cancer Res Treat. 2009 Jan;113(2):357-70
references: 18324472
references: Cancer. 2000 Jan 1;88(1):114-23
references: 10618613
references: Am J Public Health. 1987 Dec;77(12):1515-7
references: 2823619
references: Breast Cancer (Auckl). 2010 May 07;4:23-33
references: 20697530
references: Cancer. 2012 Nov 15;118(22):5463-72
references: 22544643
references: Ann Surg Oncol. 2012 Jan;19(1):253-8
references: 21725686
references: J Clin Oncol. 2006 Mar 20;24(9):1342-9
references: 16549828
references: JAMA. 2006 Jun 7;295(21):2492-502
references: 16757721
references: Breast Cancer Res Treat. 2001 Jul;68(1):33-43
references: 11678307
references: J Natl Cancer Inst. 1994 May 4;86(9):705-12
references: 7908990
references: J Natl Cancer Inst. 2002 Apr 3;94(7):490-6
references: 11929949
references: CA Cancer J Clin. 1998 Jan-Feb;48(1):31-48
references: 9449932
references: N Engl J Med. 1993 Jul 29;329(5):326-31
references: 8321261
references: Clin Cancer Res. 2010 Dec 15;16(24):6100-10
references: 21169259
references: Cancer. 2007 May 1;109(9):1721-8
references: 17387718
references: Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):151-6
references: 8467250
references: Cancer. 2007 Aug 15;110(4):876-84
references: 17620276
references: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4429-34
references: 17671126
references: Breast Cancer Res Treat. 2009 May;115(2):423-8
references: 18543098
references: Int J Breast Cancer. 2012;2012:217185
references: 22295242
references: CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93
references: 15061598
references: J Clin Oncol. 2009 Jan 10;27(2):220-6
references: 19047281
references: Rev Epidemiol Sante Publique. 2006 Sep;54(4):313-25
references: 17088696
references: J Clin Oncol. 2005 Sep 20;23(27):6639-46
references: 16170171
references: Ann Intern Med. 1996 Aug 1;125(3):173-82
references: 8686974
references: Breast Cancer Res Treat. 2004 Jun;85(3):219-22
references: 15111759
references: J Natl Cancer Inst. 2005 Mar 16;97(6):439-48
references: 15770008